Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Out-Licenses TIGIT Inhibitor to Novartis in $2.8 Billion Agreement

publication date: Dec 20, 2021

Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis oncology drugs in China outside of China's largest cities. BeiGene will receive a $300 million upfront payment, a $600-$700 million option payment within two years. $745 million in regulatory milestones and $1.15 billion in sales milestones, It will also receive royalties on sales. In January, Novartis in-licensed BeiGene's PD-1 candidate in a similar deal. Currently, BeiGene is testing the TIGIT inhibitor paired with the PD-1 in several global trials for NSCLC and other cancers. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235) (NYSE: NVS)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital